Vaccine Group Gavi Says It Has Up To $500M Available For Mpox Response
Portfolio Pulse from Benzinga Newsdesk
Vaccine Group Gavi has announced that it has up to $500 million available for the response to Mpox. This funding could potentially impact companies involved in vaccine development and distribution.
August 15, 2024 | 5:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GeoVax Labs, a company working on vaccines, could see a positive impact from Gavi's $500M funding for Mpox response.
GeoVax Labs, involved in vaccine development, might receive funding or see increased demand for its products due to Gavi's $500M allocation for Mpox.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
Moderna, a key player in vaccine development, could benefit from Gavi's $500M funding for Mpox response.
Moderna is a major vaccine developer and could potentially receive funding or increased demand for its products due to Gavi's $500M allocation for Mpox.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
SIGA Technologies, involved in antiviral treatments, may benefit from Gavi's $500M funding for Mpox response.
SIGA Technologies, which focuses on antiviral treatments, could see increased demand or funding opportunities from Gavi's $500M allocation for Mpox.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70